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Aggressive and recurrent ovarian 
cancers upregulate ephrinA5, 
a non‑canonical effector of EphA2 
signaling duality
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Erythropoietin producing hepatocellular (Eph) receptors and their membrane‑bound ligands 
ephrins are variably expressed in epithelial cancers, with context‑dependent implications to both 
tumor‑promoting and ‑suppressive processes in ways that remain incompletely understood. Using 
ovarian cancer tissue microarrays and longitudinally collected patient cells, we show here that 
ephrinA5/EFNA5 is specifically overexpressed in the most aggressive high‑grade serous carcinoma 
(HGSC) subtype, and increased in the HGSC cells upon disease progression. Among all the eight 
ephrin genes, high EFNA5 expression was most strongly associated with poor overall survival in 
HGSC patients from multiple independent datasets. In contrast, high EFNA3 predicted improved 
overall and progression‑free survival in The Cancer Genome Atlas HGSC dataset, as expected for a 
canonical inducer of tumor‑suppressive Eph receptor tyrosine kinase signaling. While depletion of 
either EFNA5 or the more extensively studied, canonically acting EFNA1 in HGSC cells increased 
the oncogenic EphA2‑S897 phosphorylation, EFNA5 depletion left unaltered, or even increased the 
ligand‑dependent EphA2‑Y588 phosphorylation. Moreover, treatment with recombinant ephrinA5 led 
to limited EphA2 tyrosine phosphorylation, internalization and degradation compared to ephrinA1. 
Altogether, our results suggest a unique function for ephrinA5 in Eph‑ephrin signaling and highlight 
the clinical potential of ephrinA5 as a cell surface biomarker in the most aggressive HGSCs.
Among epithelial ovarian cancers (OC), high-grade serous carcinoma (HGSC) is the most common and aggres-
sive subtype with 5-year survival remaining as low as 36–48%1–3. Frequently, HGSC cases are diagnosed at an 
advanced stage characterized by cancer cell dissemination into the peritoneal fluid coupled with ascites formation 
and solid metastases in peritoneal/abdominal  organs3,4. The main treatment regimen for HGSC is debulking 
surgery combined with platinum-based chemotherapy, which can be further supported by targeted treatments, 
such as poly ADP-ribose polymerase (PARP) inhibitors and bevacizumab (vascular endothelial growth factor 
blocking antibody)5–7. The addition of these targeted therapies in the treatment repertoire has increased survival 
in certain subgroups of HGSC patients, but the large majority still recur, progressively develop treatment resist-
ance, and succumb to the  disease8–10. Therefore, understanding HGSC aggressiveness is essential for further 
progress towards the development of new improved biomarkers and therapeutic strategies.
Erythropoietin producing hepatocellular (Eph) receptors, the largest family of receptor tyrosine kinases 
(RTKs), and their ligands ephrins are involved in a variety of conditions in both physiology and  disease11. The 
canonical Eph receptor signaling occurs via interactions with the ephrin ligands. In cancer, Eph receptors are, 
however, frequently upregulated in conjunction with ephrin downregulation, thus impairing receptor-ligand 
 binding12. Eph receptors are divided into two subclasses depending on the preference for their ligands: Generally, 
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EphAs bind glycosylphosphatidylinositol (GPI) membrane-anchored A-class ephrin ligands, and EphBs bind 
transmembrane B-class ephrin  ligands13,14. The signaling mediated by the ephrins and Ephs is context-dependent, 
and distinct modes of Eph receptor activation (ligand-dependent and -independent) and signaling direction 
(forward, in the Eph-expressing cell, and reverse, in the ephrin-expressing cell) promote different downstream 
signaling outcomes (tumor-suppressive vs pro-tumorigenic)11,15. In distinct OC datasets, this context-dependent 
signaling has been linked to different clinical outcomes based on, for instance, association of high EPHA2 and 
EPHA4 expression with poor patient  survival16–26. Among their ligands, opposing clinical associations have 
instead been reported for EFNA1 and EFNA516,18.
The widely studied Eph in cancer, EphA2, has been proposed as therapeutic target in OC, albeit none of the 
reported strategies have provided promising results in clinical  trials27. Upon interaction with ephrinA ligand, 
EphA2 transphosphorylation at specific cytoplasmic tyrosine residues leads to the receptor activation, followed 
by internalization of the receptor-ligand complex and eventually receptor degradation or  dephosphorylation12,28. 
This signaling mode has been mostly related to the anti-invasive and growth-suppressive cancer cell functions. 
Ligand independently, EphA2 can mediate tumor-promoting signaling via crosstalk with various growth factor 
receptors, which through AGC family kinases (Akt, PKA and RSK) promote the phosphorylation of EphA2 
S897  residue29–31. The pro-invasive EphA2 activity can also be regulated upon Src-kinase activation and limited 
cleavage by matrix metalloproteinase MT1-MMP32. Moreover, we have found that, rather than the depletion 
of total EphA2 activity, inhibition of the EphA2-pS897 signaling and coincident restoration of the canonical 
EphA2-pY588 are coupled with effective HGSC cell sensitization to platinum  chemotherapy29. Therefore, in 
addition to targeting Eph receptors, altering the signaling elicited by the ephrin ligands can help to revert the 
tumor-promoting signaling to a suppressive  state33,34.
High EFNA5 expression has been linked to poor survival in OC  patients18,20,21 although high ephrin levels in 
general are more frequently associated to favorable clinical outcome due to the transduction of tumor-suppressive 
signals upon EphA2-Y588  phosphorylation12,31. Intrigued by our observation of the opposite clinical associa-
tion of EFNA5 and EFNA3 in OC TCGA data, we sought to investigate EFNA5 and the corresponding protein 
ephrinA5 clinically and functionally in HGSC. We find here that, in addition to the strong association of high 
EFNA5 mRNA with poor HGSC patient survival, ephrinA5 protein is specifically upregulated in the most aggres-
sive HGSC tumors compared to the other histopathological OC subtypes. Functionally, our results describe a 
unique signaling pattern for ephrinA5 that, divergent from the more extensively studied ephrinA1, can even 
reduce the canonical EphA2 phosphorylation at Y588. Altogether, our findings highlight the clinical potential 
of ephrinA5 as a biomarker and a possible treatment target in HGSC.
Results
High EFNA5 expression correlates with poor HGSC patient survival. Unbiased analyses of differ-
ent OC patient cohorts have revealed survival associations for several genes encoding Eph receptors (EPHA/B) 
and ephrin ligands (EFNA/B), including contradictory  results16,18,20–22,24. To systematically investigate all the 14 
Eph receptors and 8 ephrin ligands in clinical HGSC, we analyzed overall survival (OS) and progression-free 
survival (PFS) in patients with 40% highest versus 40% lowest gene expression for all the Ephs and ephrins 
first using TCGA HGSC mRNA  dataset35 (see Supplementary Fig. 1A for cohort clinical data summary). High 
EFNA5 was associated to poor 5-year OS (Fig. 1A; Supplementary Fig. 1B; p = 0.001). This association remained 
significant with extended survival time analysis (13-year; Fig. 1B; Supplementary Fig. 1C; p = 0.010) as well as 
when k-means clustering was used for patient grouping (Supplementary Fig. 1B; p = 0.003), and high EFNA5 also 
showed a trend to shorter time to recurrence/PFS (Fig. 1C). In contrast, high EFNA3 correlated with favorable 
5-year OS (Fig. 1D; p = 0.043) as well as longer PFS (Fig. 1E; p = 0.030), whereas EFNA1 and the other ephrin 
ligands did not correlate with patient survival (Fig. 1F; Supplementary Fig. 1B, C). The associations of EFNA5 
(p < 0.001; hazard ratio (HR) = 1.80, indicating association to poor OS) and EFNA3 (p = 0.023; HR = 0.70, indi-
cating association to favorable OS) remained significant when integrating age at diagnosis, residual tumor after 
surgery and FIGO stage in a Cox multivariate analysis (Fig. 1G, H).
Out of the 14 Eph receptors, only high EPHA2 and EPHA4 correlated significantly with poor 5-year OS (Sup-
plementary Fig. 1D, E; p < 0.05), whereas high EPHA1 correlated with favorable OS (Supplementary Fig. 1B, C and 
F; p ≤ 0.040). EPHA2 association to poor OS remained significant in Cox multivariate analysis (Supplementary 
Fig. 1G; p = 0.044, HR = 1.36).
For result validation, we next used seven independent OC datasets (n = 815 HGSC patients) from a publicly 
available database with pooled mRNA data from various OC studies (curatedOvarianData36). Across these 
datasets as well as in TCGA, the genes for ephrin ligands were variably expressed; EFNA1, EFNB1 and EFNB2 
showing relatively high and EFNA2 low global expression (Supplementary Fig. 2A, B). The overall expression 
levels of the receptors EPHA1, EPHA2, EPHA4 and EPHB2 were higher than those of EPHA3, EPHA5, EPHA6, 
EPHA7, EPHA8, EPHA10 and EPHB1 (Supplementary Fig. 2A, B).
With these OC datasets, we performed multivariate analyses for OS, considering also residual tumor after sur-
gery and FIGO stage. The ligand encoding genes EFNA5 and EFNB2 correlated with poor OS (HR > 1.00, p < 0.05) 
in the combined validation datasets (Fig. 1I, Supplementary Fig. 3A, B). The receptor genes EPHA2, EPHB2 and 
EPHB4 also correlated with poor OS, whereas EPHA1 correlated with favorable OS (Supplementary Fig. 4A–E). 
Among all EFNs and EPHs, EFNA5 was one of the three genes with strongest predictive power for poor OS, 
showing the strongest association of all the ligands to OS in the multivariate analysis (Supplementary Figs. 3, 4).
Unlike EFNA1, endogenous EFNA5 is not a canonical EphA2‑pY588 signaling mediator in 
ovarian cancer cells. EphrinA-mediated EphA2 receptor tyrosine kinase activation is linked to tumor-
suppressive signaling, and thus disfavored in cancer  cells12,37,38. Considering the inverse contribution of EFNA5 
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(encoding ephrinA5) to cancer aggressiveness and poor clinical HGSC outcome, we sought to further examine 
ephrinA5 in HGSC. First, to identify a suitable functional cell model, we assessed mRNA levels for ephrins and 
Eph receptors in six human TP53 mutant HGSC cell  lines39. All ephrin genes except EFNA2 and EFNB1 were 
expressed variably, EFNA5 being relatively high in all these cell lines (Fig. 2A; the Cancer Cell Line Encyclope-
dia, CCLE, https:// porta ls. broad insti tute. org/ ccle). All the six HGSC cells were characterized by particularly 
high EPHA2, whereas the other Ephs were variably expressed and/or low (Fig. 2A) in a relatively similar manner 
as in the patients (see Supplementary Fig. 2).
To compare the effects of ephrinA1 and ephrinA5 in EphA2 activation/phosphorylation, we used the epithe-
lial HGSC cell lines OVCAR3 and  OVCAR429, which both expressed these three genes, for EFNA1 and EFNA5 
gene knockdown. Using specific pooled siRNAs, the ephrins were silenced with > 70% efficiency (Fig. 2B, C). 
In both cell lines, EphA2 was constitutively phosphorylated at Y588 and S897 amino acid residues (Fig. 2D). 

















































































































































































































































Figure 1.  Ephrin and Eph gene expression are diversely associated to survival in HGSC. (A–F) Kaplan–Meier 
survival curves illustrate the 5-year and 13-year overall survival (OS) or the progression-free survival (PFS) 
of patients with high or low (top 40% vs bottom 40%) EFNA5 (A: 5-y OS, B: 13-y OS, C: PFS), EFNA3 (D: 
5-y OS, E: PFS), and EFNA1 (F: 5-y OS) in TCGA HGSC dataset. Logrank test was used. (G, H) Multivariate 
analysis results for EFNA5 (G) and EFNA3 (H) OS associations when considering the variables age at diagnosis 
(median cutoff of 59 years), residual tumor after surgery (no vs yes) and FIGO stage (I–IIIB vs IIIC–IV). 
Cox regression was used. HR [95% CI] = hazard ratio with 95% confidence interval. (I) Overall hazard ratios 
and p values from the Cox regression tests performed to analyze ephrin survival associations in HGSC using 
the curatedOvarianData database. Significant associations between poor OS and high ligand expression are 
indicated in red. # = number of included datasets.
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of the ligand-mediated signaling, EFNA5 silencing left EphA2-pY588 essentially unaltered in OVCAR3 and 
even increased this tyrosine phosphorylated receptor in OVCAR4 (Fig. 2D, E). Compared to control cells, the 
oncogenic EphA2-pS897 was increased after silencing of either EFNA1 or EFNA5 (Fig. 2D, F), whereas total 
EphA2 was less affected, or increased after EFNA5 silencing in OVCAR3 (Fig. 2D, G). These results suggest that 
while endogenous ephrinA1 mediates the canonical EphA2-Y588 phosphorylation, ephrinA5 has a different 
function with potential to instead limit this tumor-suppressive EphA2-pY588.
EphrinA5 is an inefficient activator of EphA2‑pY588 signaling and receptor internalization 
compared to ephrinA1. To better understand the unexpected contribution of ephrinA5 to EphA2 signal-
ing, OVCAR3 and OVCAR4 were treated with dimeric (Fc-tagged) and monomeric (His-tagged) recombinant 
ephrinA1 and ephrinA5 for 120 min. Both ephrinA1 and ephrinA5 were detected bound to the cells after the 
treatment (Supplementary Fig. 5B). As described above, EphA2 was constitutively phosphorylated both at Y588 
and S897 residues in OVCAR3 and OVCAR4 (Fig. 3A). While treatment with ephrinA1 (Fc- and His-tagged) 
increased the tumor-suppressive EphA2-pY588 in these cells, as expected upon ligand-mediated receptor activa-
tion, this phosphorylation was not altered by ephrinA5 (Fc- and His-tagged) in OVCAR3 and remained lower 
in OVCAR4, compared to the respective ephrinA1 (Fc- and His-tagged) treated cells (Fig. 3A, B). The oncogenic 
EphA2-pS897 was reduced by ephrinA1 (Fc- and His-tagged) in OVCAR4, and by ephrinA5-His treatment 
in both cells (Fig.  3A, C). Total EphA2 remained unaltered/unaffected upon treatments with the exogenous 
ligands under these experimental conditions, except for a reduction upon ephrinA1-His treatment in OVCAR4 
(Fig. 3A; Supplementary Fig. 5C).
To elucidate putative differences in EphA2 internalization occurring after activation by ephrinA1 or eph-
rinA5, we assessed the localization of this receptor by immunofluorescence in HGSC cells after treatment with 
the dimeric Fc-tagged ephrins for 45 min (treatment time adjusted to efficient EphA2 activation by the dimeric 
 ephrins40). Prominent cell surface localization of EphA2 detected in control cells was lost and the total EphA2 
intensity reduced in OVCAR3, OVCAR4 as well as in the third, more mesenchymal HGSC cell line,  OVCAR829, 
after ephrinA1 treatment (Fig. 3D, E), indicating EphA2 internalization and degradation. Markedly, ephrinA5 
treatment had minor effects on EphA2 localization and resulted in only slightly reduced signal intensity in 
OVCAR3 and OVCAR8 (Fig. 3D, E). Of note, EphA2 intensity remained significantly higher in these HGSC 
cells after ephrinA5 treatment compared to ephrinA1 treatment (Fig. 3D, E; OVCAR3: p = 0.009, OVCAR4: 
p < 0.001, OVCAR8: p = 0.002).
EphrinA5 is expressed in the cancer cells and strongly associates with the most aggressive 


















































































































































































Figure 2.  Canonical EphA2-pY588 activation remains unaltered or is even increased after depletion of EFNA5. 
(A) Heat map for ephrin ligands and Eph receptor mRNAs in selected HGSC cell lines. Data obtained from 
CCLE and illustrated per cell line. (B, C) Quantification of EFNA1 (B) and EFNA5 (C) mRNAs in OVCAR3 
and OVCAR4 with silenced EFNA1 or EFNA5 compared to the controls. N = 3. siScr is set to one. (D–G) EphA2 
(total and phosphorylated) in OVCAR3 and OVCAR4 after silencing of EFNA1 or EFNA5 (D) along with 
EphA2-pY588 (E), EphA2-pS897 (F), and EphA2 (G) quantifications. N = 3. siScr is set to one. Full-length blots 
are presented in Supplementary Fig. 5. p values (Student’s t-test): *< 0.05; **< 0.01.
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in clinical OC tumors, we first analyzed this protein in different tissue compartments of a large treatment-naïve, 
primary HGSC section by immunohistochemistry (IHC). Compared to the surrounding tissue, ephrinA5 levels 
were generally stronger in the HGSC cells, showing patterns of segregated, high and relatively lower ephrinA5 
expressing tumor areas (Fig. 4A, a–d). The tumor stroma showed mainly negative to low expression with some 
ephrinA5 positivity in vessel-like structures (Fig. 4A, e–f).
To investigate the relevance of this ephrin ligand among the different OC subtypes, we assessed ephrinA5 
expression in 392 epithelial OC and benign tissue samples by IHC of tissue microarrays (TMAs). See exam-
ples for grading from negative to strong expression in Fig. 4B. Among all epithelial OC subtypes and benign 
tissues, HGSC comprising the most aggressive tumors had the highest overall ephrinA5 expression (Fig. 4C; 
p = 9.00 ×  10−6), supporting the strong association between ephrinA5 and OC malignancy.
EphrinA5 increases during disease progression in patient‑derived HGSC cells. To investigate 
the changes in ephrinA5 expression upon disease progression, considering the prominent protein expression 
particularly in the cancer cells, we collected ascites cells longitudinally from a HGSC patient at three time points 
including diagnosis, interval (after three rounds of platinum chemotherapy) and relapse. The isolated cells were 
84–94% positive for the nuclear HGSC marker PAX8 (Fig. 5A). Immunofluorescence of ephrinA5 coupled with 
the cell surface marker CD44 allowed us to investigate the expression of this ligand in the samples enriched for 
cancer cells. EphrinA5 was essentially undetectable in this diagnosis sample and expressed at low levels in HGSC 
cells from the chemotherapy-treated interval time point of the same patient (Fig. 5B). Notably, cells from the 
relapse time point had higher expression of ephrinA5 compared to cells from the earlier diagnosis and interval 
stages of this patient’s longitudinal samples (Fig. 5B, C).
To uncover more comprehensive expression changes of the ephrins and Eph receptors upon HGSC progres-
sion, we analyzed RNA sequencing data of ascites samples from four HGSC patients at the times of diagnosis 
and relapse of the disease. These samples were characterized by high expression of the epithelial markers KRT7 
and EPCAM, and lower to very low expression of immune cell (CD45, CD3) and fibroblast (FAP, PDGFRB) 
markers (Fig. 5D). In contrast to decreased EFNA3 expression, EFNA5 was significantly increased from the time 
of diagnosis to relapse (Fig. 5E; EFNA3: p = 0.015, EFNA5: p = 0.038). In these same HGSC samples, EFNB2 was 
likewise increased, whereas EFNA1, EPHA1, EPHA2, EPHA4, EPHB2 and EPHB4 expression remained essentially 
unaltered (Fig. 5E; EFNB2: p = 0.005). These results correlate with the above survival associations, where low 
EFNA3 showed association to short PFS and high EFNA5 and EFNB2 were associated with poor OS (see Fig. 1). 
Figure 3.  EphA2 activation by ephrinA5 results in weaker canonical EphA2-pY588 signaling than upon 
ephrinA1-mediated activation. (A–C) EphA2 (total and phosphorylated at Y588 or S897) in OVCAR3 
and OVCAR4 after treatment with soluble recombinant dimeric (Fc-tagged) and monomeric (His-tagged) 
ephrinA1 and ephrinA5 for 120 min were assessed by immunoblotting (A) and quantified for EphA2-pY588 
(B) and EphA2-pS897 (C). N = 3. Full-length blots are presented in Supplementary Fig. 5. (D, E) Fluorescent 
micrographs of EphA2 (red) and EpCAM (green) in ephrinA1-Fc and ephrinA5-Fc treated OVCAR3, 
OVCAR4, and OVCAR8 cells (D) and corresponding EphA2 quantification (E). N = 3 (OVCAR3) or 4 
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Altogether, these data suggest that the uniquely acting ephrinA5 can contribute to the abysmal HGSC patient 
outcome upon upregulation in the malignant HGSC cells and during progression of the disease.
Discussion
The tumor-suppressive signaling elicited by EphA2-ephrinA complexes is often halted in aggressive cancers via 
EphA2 receptor overexpression coupled with ephrinA ligand  downregulation12. Yet, the epithelial OC cells display 
variable ephrinA/EFNA expression (see Fig. 2A) and high mRNA expression of EFNA5, encoding the ephrinA5 
ligand, has been repeatedly associated to poor survival in OC  patients18,20,21. Here we show that ephrinA5 protein 
levels are high specifically in the most aggressive HGSC and further upregulated transcriptionally upon disease 
progression. Functionally, we describe an unusual signaling pattern for this ligand in HGSC cells, whereby it 
leaves unaffected or even impairs the canonical, tumor-suppressive tyrosine phosphorylation and subsequently 
induced internalization and degradation of EphA2 receptor.
Unbiased analyses of independent OC cohorts have revealed survival associations of individual Eph and 
ephrin genes, resulting in an incomplete understanding of the clinical importance of the distinct receptors and 
ligands in this  disease16,18,20–22,24. Here we report that, in line with the canonical function of ephrins in promot-
ing tumor-suppressive Eph receptor  signaling12, low EFNA3 mRNA levels are associated to poor OS and short 
PFS in the TCGA HGSC dataset. In contrast, high EFNA5 expression is associated to poor survival in HGSC. In 
agreement with previous  reports16–18,20–22, our systematic analysis of all the 22 genes for Eph receptors (EPHs) 
and ephrin ligands (EFNs) concurs with the association of high EFNB2, EPHA2, EPHB2 and EPHB4 with poor 
OS. For the Ephs/ephrins with previously reported inconsistent  findings16,18,22,24, our analysis supports the cor-
relation of low EPHA1 mRNA expression with poor OS, whereas the analyzed data lacked significant association 
for EFNA1.
Recurrence and development of treatment resistance in HGSC patients remains an unmet clinical need and 
thus understanding these processes at the functional level is essential to provide new therapeutic opportunities. 
Figure 4.  EphrinA5 protein expression is heterogeneous and associates with disease malignancy. (A) EphrinA5 
IHC of a diagnosis-stage, treatment-naïve, primary HGSC tumor. Magnified images for different tumor areas. 
(B) Representative images of ephrinA5 IHC used for scoring the ovarian tumor TMAs. (C) Correlation of 
ephrinA5 protein expression with different epithelial OC subtypes and benign tumors ordered according to 
the weighted arithmetic mean of ephrinA5 score (descending order). t = tissue type, M = malignant, B = benign, 
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We show here that ephrinA5 protein as well as mRNA expression in ascites-derived HGSC cells was increased 
in post-treatment samples upon disease progression. Previous studies have explored the interactions of EphA2 
with ephrinA1 and ephrinA5 and the corresponding crystal structures for these Eph/ephrin complexes have 
been  resolved41–43. However, the signaling mechanisms elicited by endogenous ephrinA5 in cancer cells as well 
as the differences between ephrinA1- and ephrinA5-mediated EphA2 receptor activation have remained elu-
sive. Further studies will be of interest to fully understand the complex Eph/ephrin signaling mechanisms and 
outputs, with possible heterotypic Eph-Eph and Eph-growth factor receptor crosstalk, alternative binding of 
ephrinA ligands to EphB receptors (including ephrinA5-EphB2 interaction, as occurs in neural development) 
and vice versa (e.g. ephrinB2-EphA4, as reported in the context of monocyte adhesion to endothelial cells), 
proteolytic ligand and/or receptor cleavages, as well as ephrin ligand crosstalk with other  RTKs28,44,45. Nonethe-
less, our current results provide evidence indicating that ephrinA5 can hinder the tumor suppressive signaling 
normally coupled with degradation of EphA2, thus allowing the oncogenic receptor to function at the HGSC 
cell membranes. We have recently described a strategy to sensitize HGSC cells to chemotherapy by blocking the 
platinum-induced, pro-tumorigenic EphA2-pS897 signaling and simultaneously restoring EphA2 phosphoryla-
tion at  Y58829. Disrupting the balance of the canonically acting ephrinAs and the tumor promoting ephrinA5 
could likewise help to restore the tumor-suppressive signaling through EphA2-Y588 phosphorylation in order 
to reduce tumor malignancy and development of the increasingly therapy resistant relapses.
In this study we describe a specific link between high ephrinA5 protein expression and HGSC, the most 
aggressive epithelial OC subtype, and show that ephrinA5 increases upon disease progression and associates 
to poor survival. We further report a non-canonical signaling function for ephrinA5 in HGSC cells, whereby, 
opposite to the tumor-suppressive signaling elicited by EphA2-ephrinA1 complexes, ephrinA5 even limits the 
canonical activation of EphA2 through phosphorylation at Y588. Our findings suggest the potential use of 
ephrinA5 as an indicator of disease subtype and progression stage, as well as its relevance as a putative survival 
biomarker in HGSC.
Methods
Antibodies and reagents. The following antibodies were used: anti-CD44/HCAM (sc-7297, Santa Cruz, 
immunofluorescence (IF): 1:400), anti-CK7 (YM3054, ImmunoWay, IF: 1:600), anti-EpCAM (#2929, Cell Sign-
aling Technologies, IF: 1:800), anti-EphA2 ECD (AF3035, R&D Systems, immunoblot (IB): 1:1000, IF: 1:100), 
anti-EphA2-pS897 (#6347, Cell Signaling Technologies, IB: 1:1000), anti-EphA2-pY588 (#12677, Cell Signaling 
Technologies, IB: 1:1000), anti-ephrinA1 (sc-911, Santa Cruz, IB: 1:1000), anti-ephrinA5 (ab60705, Abcam, IB: 
1:1000, IF: 1:100, immunohistochemistry (IHC): 1:200), anti-ephrinA5 (38-0400, Life Technologies, IF: 1:100), 
anti-GAPDH (G8795, Sigma-Aldrich, IB: 1:10000), anti-PAX8 (10336-1-AP, Proteintech, IF: 1:100), anti-mouse 
Figure 5.  EphrinA5 increases upon HGSC progression in patient-derived HGSC cells. (A) Fluorescent 
micrographs of cytokeratin-7 (CK7, green) and PAX8 (pink) in cancer cells isolated from HGSC patient ascites 
at the time of diagnosis, interval and relapse. Percentage of PAX8 positivity (average of 3 images/clinical time 
point) is indicated in the micrographs. N = 1 patient, 3 clinical time points. (B, C) Fluorescent micrographs 
of ephrinA5 (green) and CD44 (red) in the set of longitudinal HGSC patient-derived ascites cells shown in A 
(B) and corresponding ephrinA5 quantification in CD44+ cells (C). N = 1 patient, 3 clinical time points (B), 3 
images/clinical time point with 91–215 ascites-derived cells per image (C). Intensity at diagnosis is set to one. 
(D) Heatmap of averaged mRNA expression for the epithelial (KRT7, EPCAM), immune cell (CD45, CD3) and 
fibroblast (FAP, PDGFRB) markers in samples included in (E). (E) Chart illustrates changes in EFNA1, EFNA3, 
EFNA5, EFNB2, EPHA1, EPHA2, EPHA4, EPHB2 and EPHB4 mRNAs in HGSC patient-derived ascites cells 




Scientific Reports |         (2021) 11:8856  | https://doi.org/10.1038/s41598-021-88382-6
www.nature.com/scientificreports/
HRP-conjugate (P0260, Dako, IB: 1:2000), anti-rabbit HRP-conjugate (P0448, Dako, IB: 1:2000), anti-goat HRP-
conjugate (P0449, Dako, IB: 1:2000), anti-goat Alexa Fluor 568 conjugate (A11057, Thermo Scientific, IF: 1:500), 
anti-mouse Alexa Fluor 488-conjugate (A21202, Life Technologies, IF: 1:500), anti-rabbit Alexa Fluor 568-con-
jugate (A11036, Thermo Scientific, IF: 1:500). For mounting, Vectashield with 4′,6-diamidine-2-phenylindole 
dihydrochloride (DAPI; H-1200, Vector Laboratories) was used. The following recombinant proteins were used: 
ephrinA1-Fc (6417-A1, R&D Systems, 1  µg/ml), ephrinA1-His (10,882-H08H, Life Technologies, 1  µg/ml), 
ephrinA5-Fc (374-EA, R&D Systems, 1 µg/ml), ephrinA5-His (10,192-H08H, Life Technologies, 1 µg/ml), and 
IgG-Fc (110-HG, R&D Systems, 1 µg/ml).
Cell lines. Human HGSC cell lines OVCAR3, OVCAR4, and OVCAR8 (National Cancer Institute, U.S.) were 
cultured in RPMI-1640 (Sigma-Aldrich) supplemented with 10% fetal bovine serum (Gibco), 1% penicillin and 
streptomycin (Gibco), 1% glutaMAX (Gibco), and 10 µg/ml human insulin (OVCAR3 only, Sigma-Aldrich). 
Cells were cultured according to manufacturer´s instructions and checked routinely for mycoplasma contami-
nation using MycoAlertPlus Mycoplasma Detection Kit (Lonza).
Patient samples. All studies involving clinical material were performed in accordance with the ethical 
standards laid in the 1975 Declaration of Helsinki. Each patient gave written informed consent, and tissue and 
ascites specimens were collected from consented patients at the Department of Obstetrics and Gynecology, 
Turku University Central Hospital. The study protocol and use of all material was approved by The Ethics Com-
mittee of the Hospital District of Southwest Finland (ETMK: ETMK145/1801/2015) and the Hospital District 
of Helsinki and Uusimaa (HUS: HUS359/2017).The clinical material was collected under the auspices of Auria 
Biobank.
Treatment-naïve, primary HGSC tumor was collected at the time of debulking surgery and subsequently 
formalin-fixed and paraffin-embedded to later be used for immunohistochemical stainings.
Fresh patient-derived ascites fluid was collected at the time of diagnosis and longitudinally at interval and 
relapse-stages and processed for ex vivo cultures as described by Moyano-Galceran et al29. Longitudinal ascites-
derived cells were simultaneously grown on glass coverslips and stained by immunofluorescence to assess cancer 
cell purity.
RNA sequencing. Ascites-derived cells from diagnosis and relapse-stage (n = 4 samples/clinical time point) 
were used for paired-end RNA-sequencing. Total RNA was extracted from fresh ascites-derived cells by using 
RNeasy kit (Qiagen) with DNase I treatment according to manufacturer’s instructions. RNA quality and con-
centration were tested by Bioanalyzer 2100 (Agilent). Paired-end 100 bp RNA-seq producing around 60M reads 
was carried out on Illumina HiSeq4000 platform and the data was processed using SePIA, a comprehensive 
RNA-seq data processing  workflow46. Read pairs were trimmed using Trimmomatic, and trimmed reads were 
aligned to the reference genome (GRCh38.d1.vd1) using STAR (version 2.5.2b), allowing up to 10 mismatches, 
and all alignments for a read were  output47. Gene level expression was quantified as log2(TMP + 1), where TPM 
is transcript per million as calculated by eXpress (version 1.5.1-linux_x86_64)48. See the section Data Availability 
for information on data deposition at the European Genome-phenome Archive.
Tissue microarrays (TMAs). Tumor samples were collected, analyzed and processed to generate 2 TMAs 
as previously  described49. The TMAs were composed of high-grade serous carcinoma (n = 204), low-grade 
serous carcinoma (n = 20), serous borderline tumor (n = 15), serous cystadenoma (n = 14), mucinous carcinoma 
(n = 49), mucinous cystadenoma (n = 12), endometroid carcinoma (n = 43), clear cell carcinoma (n = 29), undif-
ferentiated carcinoma (n = 4), and Brenner tumor (n = 2).
siRNA knockdown. SMARTpool siRNAs (Dharmacon) against human EFNA1 (L-006369-00), EFNA5 
(L-011649-00), and non-targeting siRNA (D-001206-14) were transfected in cells using Lipofectamine 2000 
(Life Technologies).
Immunoblotting. Cells were lysed in RIPA buffer (50  mM Tris–HCl pH 7.4, 150  mM NaCl, 1% Igepal 
CA-630, 0.5% sodium deoxycholate) containing cOmplete protease inhibitor cocktail (Roche), 1 mM sodium 
orthovanadate (Sigma-Aldrich) and 5 mM EDTA. Conditioned medium was collected, centrifuged at 21,000 g 
for 15 min at 4 °C and processed as the cell lysates. Protein content was assessed with BCA-kit (Pierce). Lysates 
mixed with 5 × sample buffer [25% v/v glycerol (Sigma-Aldrich), 0.125  M Tris (Sigma-Aldrich), 0.5  M SDS 
(Sigma-Aldrich), 0.5 mg/ml bromophenol blue (Sigma-Aldrich), 0.1 M DTT (Life Technologies)] were size-
fractionated by gradient (4–20%) SDS-PAGE gel (Bio-RAD) followed by transfer to nitrocellulose membranes 
(Bio-RAD). The non-specific protein binding sites were blocked for 30 min with 5% non-fat milk or 5% BSA 
(Biowest) and the membranes were probed with primary antibodies overnight at 4  °C. HRP-conjugated sec-
ondary antibodies (Dako) were applied for 1 h at room temperature (RT). Bands were detected by applying 
enhanced ECL chemiluminescence reagent (GE Healthcare) using x-ray films (Fujfilm) and developed in a Pro-
tec OPTIMAX 2010 film processor.
Immunohistochemistry. The staining of TMAs and bulk tumor sample was performed with automated 
immunostaining device BenchMark XT (Roche Diagnostics/Ventana Medical Systems) using Ultraview Univer-
sal DAB Detection Kit (Roche Diagnostics/Ventana Medical Systems).
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Immunofluorescence. Cells were fixed with 4% paraformaldehyde for 20 min and subjected to blocking 
and permeabilization with 5% BSA in PBS containing 0.1% Triton X100 for 30 min at RT. Cells were incubated 
for 1 h in pre-titrated dilutions of primary antibodies in blocking buffer, followed by thorough washes with PBS, 
and incubation with Alexa-conjugated secondary antibodies for 30 min. Cells were subsequently washed and 
mounted with Vectashield (Vector Laboratories) containing DAPI. To enhance nuclear PAX8 staining, cells were 
post-fixed with absolute ethanol for 45 s before blocking.
Image analysis and statistics. Quantitative assessment of immunoblots was performed using ImageJ. 
Immunofluorescence images were obtained using Zeiss AxioImager.Z1 microscope outfitted with an ApoTome 
optical sectioning device and a 20 × Plan Apochromat air objective. Images were processed using Zen 2012. 
Quantification was performed with CellProfiler 3.0.0., by using DAPI-stained nuclei as primary objects, then 
propagating the cytoplasmic area from nuclei using a membrane-localizing marker to map the edges of cyto-
plasm, and finally forming the analysis area by subtracting the nuclear area from each cytoplasm. Mean signal 
intensities were then obtained from each image and averaged for each treatment/condition. The experimental 
protein and RNA analyses were performed at least in triplicates, as indicated in the corresponding figure legends, 
and the statistical significance was determined using two-sided Student t-test. p values are depicted as *p < 0.05; 
**p < 0.01; ***p < 0.001.
For the TMA scoring, a 4-point scale (0: negative, 1: weak, 2: intermediate, and 3: strong) was used to evaluate 
the maximum intensity of ephrinA5 staining in each core. The scoring was performed independently and in a 
blinded manner by two investigators, and in case of disagreement, a consensus score was established. Correlation 
analyses from TMA data were performed through Pearson chi-square test.
The 2011 Agilent 244 K microarray-sequenced HGSC TCGA  dataset35 was used for the survival association 
analysis. Overall survival (OS) was defined as the interval from the date of initial surgical resection to the date 
of last follow-up or death, in months. Progression-free survival (PFS) was defined as the timeframe from the 
date of initial surgical resection to the date of progression, recurrence, or last follow-up, in months. Cases that 
were healthy (n = 8), from different primary site than ovary/fallopian tube (n = 4), low-grade (n = 87), or with 
no information regarding histology or neoadjuvant chemotherapy (n = 48) were excluded from the analysis. 
Differences in 5-year and 13-year OS, as well as PFS in 40% highest versus 40% lowest Eph-receptor/ephrin 
expressing patients were estimated using log-rank test. The 40% cutoff was adopted to include the maximum 
number of samples while minimizing the noise produced by ambiguous samples. K-means clustering was also 
used for analyzing 5-year OS. Cox multivariate analysis integrating the variables age at diagnosis (median cutoff 
of 59 years), residual tumor after surgery (no vs yes) and FIGO stage (I–IIIB vs IIIC–IV) was also performed to 
evaluate 5-year OS. TCGA statistics were performed in SPSS, versions 24.0 and 26.0.
The curatedOvarianData, a manually curated data collection of microarray data for altogether 2970 OC 
patients from 23 studies with documented clinical metadata, was used to validate our Eph-ephrin survival asso-
ciation results in a broader OC  setting36. The datasets were filtered to include only those that had information 
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on vital status, time to death/last follow up, residual tumor after surgery and FIGO stage, and contained at least 
60 cases and expression for at least 1000 genes. The TCGA cohort (both the RNA sequencing and microarray 
datasets) in curatedOvarianData was excluded to generate the validation cohort. From the selected datasets 
(n = 7), cases that complied with sample type (tumor), histology type (serous), stage (late) and grade (high) were 
included in the analyses. The batch corrected mRNA expression of the 8 ephrin ligands and 14 Eph receptors 
in these filtered datasets (n = 815 patients) was plotted in a heat map using  Heatmapper50 and compared to the 
expression from the TCGA cohort (including both RNA sequencing and microarray data). Multivariate analyses 
considering residual tumor after surgery (optimal vs suboptimal debulking) and FIGO stage (I to IV) were per-
formed using RStudio. The hazard ratios with 95% confidence interval (CI) and the corresponding significance 
for all Eph-ephrin associations to OS were obtained and plotted in forest plots using RStudio.
The Affymetrix U133 + 2 mRNA sequencing data from the Cancer Cell Line Encyclopedia (CCLE) was 
obtained from the dataset uploaded on 29th of September 2012 and used for the Eph/ephrin expression analysis 
in the cell lines. The probe IDs are collected in Table 1. 
Data availability
All data generated or analyzed during this study are included in this published article and its supplementary 
information file. The bulk RNA sequencing data that support the findings of this study are available at European 
Genome-phenome Archive: EGAD00001006456 (RNA sequencing data of HGSC samples, under the study: 
EGAS00001004714). Publicly available data were obtained through The Cancer Genome Atlas (http:// cance 
rgeno me. nih. gov/), Bioconductor (http:// www. bioco nduct or. org/ packa ges/2. 12/ data/ exper iment/ html/ curat 
edOva rianD ata. html) and The Cancer Cell Line Encyclopedia (https:// porta ls. broad insti tute. org/ ccle). Further 
details are available from the corresponding author on reasonable request.
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